Matches in SemOpenAlex for { <https://semopenalex.org/work/W2511771738> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2511771738 endingPage "e11520" @default.
- W2511771738 startingPage "e11520" @default.
- W2511771738 abstract "e11520 Background: Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines, taxanes and trastuzumab are limited. Lapatinib, an oral receptor tyrosine kinase inhibitor, targeting both the human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor (EGFR), is active in combination with capecitabine in women with HER2-positive advanced breast cancer. The retrospective study purpose is to assess the safety and efficacy of the 21-day schedule of lapatinib plus capecitabine in a nonselected population, as applied in the every-day practice of our department. Methods: We retrospectively reviewed data from 27 patients treated with lapatinib at a dose of 1,250 mg per day continuously plus capecitabine at a dose of 2,000 mg per square meter of body surface area on days 1 through 14 of a 21-day cycle from June 2007 to January 2010. It is of interest that this group of patients was heavily pretreated with taxanes (100%), anthacyclines (74%), trastuzumab (81%), and other chemotherapeutic drugs. They had received median 4 prior lines of chemotherapy for metastatic breast cancer. Results: Complete response (CR) was achieved in 2 patients (8%), partial response (PR) in 9 (33%), and stable disease (SD) in 3 (11%). The median time to progression was 23 weeks and the overall survival 73 weeks. The most common adverse events were diarrhea, vomiting, hand and foot syndrome, fatigue, and rash. Most adverse events were grade I and II. Grade III toxicities included diarrhea (11%), fatigue (4%), hand and foot syndrome (8%), vomiting (4%), and instability (4%). No toxic death occurred. Conclusions: The 21-day schedule was well tolerated and effective in heavily-pretreated women with HER2-positive advanced breast cancer. No significant financial relationships to disclose." @default.
- W2511771738 created "2016-09-16" @default.
- W2511771738 creator A5004953014 @default.
- W2511771738 creator A5008975372 @default.
- W2511771738 creator A5032060765 @default.
- W2511771738 creator A5050020726 @default.
- W2511771738 creator A5056518441 @default.
- W2511771738 creator A5057164541 @default.
- W2511771738 creator A5059208130 @default.
- W2511771738 creator A5063001042 @default.
- W2511771738 creator A5074828173 @default.
- W2511771738 creator A5086201641 @default.
- W2511771738 date "2010-05-20" @default.
- W2511771738 modified "2023-09-26" @default.
- W2511771738 title "Efficacy and safety of the combination of lapatinib plus capecitabine for HER2-positive advanced breast cancer." @default.
- W2511771738 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.e11520" @default.
- W2511771738 hasPublicationYear "2010" @default.
- W2511771738 type Work @default.
- W2511771738 sameAs 2511771738 @default.
- W2511771738 citedByCount "0" @default.
- W2511771738 crossrefType "journal-article" @default.
- W2511771738 hasAuthorship W2511771738A5004953014 @default.
- W2511771738 hasAuthorship W2511771738A5008975372 @default.
- W2511771738 hasAuthorship W2511771738A5032060765 @default.
- W2511771738 hasAuthorship W2511771738A5050020726 @default.
- W2511771738 hasAuthorship W2511771738A5056518441 @default.
- W2511771738 hasAuthorship W2511771738A5057164541 @default.
- W2511771738 hasAuthorship W2511771738A5059208130 @default.
- W2511771738 hasAuthorship W2511771738A5063001042 @default.
- W2511771738 hasAuthorship W2511771738A5074828173 @default.
- W2511771738 hasAuthorship W2511771738A5086201641 @default.
- W2511771738 hasConcept C121608353 @default.
- W2511771738 hasConcept C126322002 @default.
- W2511771738 hasConcept C143998085 @default.
- W2511771738 hasConcept C197934379 @default.
- W2511771738 hasConcept C2775930923 @default.
- W2511771738 hasConcept C2777329042 @default.
- W2511771738 hasConcept C2777909004 @default.
- W2511771738 hasConcept C2778570526 @default.
- W2511771738 hasConcept C2779786085 @default.
- W2511771738 hasConcept C2908647359 @default.
- W2511771738 hasConcept C526805850 @default.
- W2511771738 hasConcept C530470458 @default.
- W2511771738 hasConcept C71924100 @default.
- W2511771738 hasConcept C90924648 @default.
- W2511771738 hasConcept C99454951 @default.
- W2511771738 hasConceptScore W2511771738C121608353 @default.
- W2511771738 hasConceptScore W2511771738C126322002 @default.
- W2511771738 hasConceptScore W2511771738C143998085 @default.
- W2511771738 hasConceptScore W2511771738C197934379 @default.
- W2511771738 hasConceptScore W2511771738C2775930923 @default.
- W2511771738 hasConceptScore W2511771738C2777329042 @default.
- W2511771738 hasConceptScore W2511771738C2777909004 @default.
- W2511771738 hasConceptScore W2511771738C2778570526 @default.
- W2511771738 hasConceptScore W2511771738C2779786085 @default.
- W2511771738 hasConceptScore W2511771738C2908647359 @default.
- W2511771738 hasConceptScore W2511771738C526805850 @default.
- W2511771738 hasConceptScore W2511771738C530470458 @default.
- W2511771738 hasConceptScore W2511771738C71924100 @default.
- W2511771738 hasConceptScore W2511771738C90924648 @default.
- W2511771738 hasConceptScore W2511771738C99454951 @default.
- W2511771738 hasIssue "15_suppl" @default.
- W2511771738 hasLocation W25117717381 @default.
- W2511771738 hasOpenAccess W2511771738 @default.
- W2511771738 hasPrimaryLocation W25117717381 @default.
- W2511771738 hasRelatedWork W2087172906 @default.
- W2511771738 hasRelatedWork W2268282207 @default.
- W2511771738 hasRelatedWork W2406422093 @default.
- W2511771738 hasRelatedWork W2589300107 @default.
- W2511771738 hasRelatedWork W2615274570 @default.
- W2511771738 hasRelatedWork W2769802777 @default.
- W2511771738 hasRelatedWork W2801864212 @default.
- W2511771738 hasRelatedWork W3026789962 @default.
- W2511771738 hasRelatedWork W4252611139 @default.
- W2511771738 hasRelatedWork W813798061 @default.
- W2511771738 hasVolume "28" @default.
- W2511771738 isParatext "false" @default.
- W2511771738 isRetracted "false" @default.
- W2511771738 magId "2511771738" @default.
- W2511771738 workType "article" @default.